A guideline for the management of women at substantially increased risk of breast cancer development

Journal of B.U.ON.

Volumn 10, Issue 4, 2005, Pages 443-458

  Trafalis, Dimitrios T P ^a,b   Athanassiou, Athanassios E ^a  

^a METAXA CANCER HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Breast cancer; Familial risk; Guidelines; Prevention; Recommendation; Women at high risk

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; BRCA2 PROTEIN; PLACEBO; RALOXIFENE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARE; BREAST SELF EXAMINATION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER STATISTICS; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROL STRATEGY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; ENDOMETRIUM CANCER; EVIDENCE BASED PRACTICE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HETEROZYGOTE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IONIZING RADIATION; LUNG EMBOLISM; MAMMOGRAPHY; MASTECTOMY; MEDICAL SPECIALIST; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARIECTOMY; OVARY CANCER; PATIENT COUNSELING; PATIENT REFERRAL; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SECOND CANCER; THROMBOEMBOLISM; VAGINA DISCHARGE;

EID: 33344469443     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. US Department of Health and Human Services. Agency for Health Care Policy and Research. Acute pain management: operative or medical procedures and trauma. Rockville (MD): The Agency, 1993. Clinical Practice Guideline No. 1. AHCPR Publication No. 92-0023, p 107.
2. Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. Br Med J 1998; 316: 1232-1235.
3. Canadian Cancer Society: National Cancer Institute of Canada. Canadian cancer statistics 1999. Toronto, 1999.
4. Ferlay J, Black RJ, Whelan SL, Parkin DM. C15VII: electronic database of cancer incidence in five continents. Lyon, France: IARC, 1997.
5. International Agency for Research on Cancer. Cancer incidence in five continents VI. IARC scientific publications No. 120. Lyon, France: IARC, 1992.
6. Information and Statistics Division. Scottish Health Statistics 1997. Edinburgh: ISD, National Health Service in Scotland, 1998.
7. Harris V, Sandridge AL, Black RJ, Brewster DH, Gould A. Cancer Registration Statistics Scotland, 1986-1995. Edinburgh: ISD Scotland Publications, 1998.
8. Vogel VG. Tools for evaluating a patient's 5-year and lifetime probabilities. Postgrad Med 1999; 105: 49-60.
9. Feuer EJ, Wun LM, Boring CC et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993; 85: 890-892.
10. Hutter RVP, Albores-Saavedra J, Anderson E et al. Is "fibrocystic disease" of the breast pre-cancerous?. Arch Pathol Lab Med 1986; 110: 171-173.
11. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
12. Eeles R, Cole T, Taylor R et al. Prophylactic mastectomy for genetic predisposition to breast cancer: the proband's story. Clin Oncol 1996; 8: 222-225.
13. Page DL, Kidd Jr TE, DuPont WD et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991; 22: 1232-1239.
14. Salvadori B, Bartoli C, Zurrida S et al. Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer 1991; 27: 35-37.
15. Ottesen GL, Graversen HP, Blihert-Toft M et al. Lobular carcinoma in situ of the female breast: The Danish Breast Cancer Cooperative Group: short term results of a prospective nationwide study. Am J Surg Pathol 1993; 17: 14-21.
16. Talamonti MS. Management of ductal carcinoma in situ. Semin Surg Oncol 1996; 12: 300-313.
17. Lagios MD, Silverstein MJ. Ductal carcinoma in situ. A shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin North Am 1997; 6: 385-392.
18. Healey EA, Cook EF, Orav EJ et al. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993; 11: 1545-1552.
19. Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and prognosis in stage 1 (T1N0M0) and stage II (T1N1M0) patients with 20 year follow-up. Surgery 1989; 106: 904-910.
20. Fracchia AA, Borgen PI. Bilateral breast cancer. Semin Surg Oncol 1991; 7:300-305.
21. Easton DF, Bishop DT, Ford D et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678-701.
22. Ford D, Easton DF, Bishop DT et al. Risk of cancer in BRCA1 mutation carriers. Lancet 1994; 343: 692-695.
23. Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary cancer. Am J Epidemiol 1992; 136: 937-948.
24. Anderson DE, Badzioch MD. Bilaterality in familial breast cancer patients. Cancer 1985; 56: 2092-2098.
25. Boice Jr JD, Harvey EB, Blettner M et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992; 326: 781-785.
26. Lesser ML, Rosen PP, Kinne DW. Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982; 91: 234-240.
27. Lee JSY, Grant CS, Donohue JH et al. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 1995; 118: 640-648.
28. Robbins GF, Berg JW. Bilateral primary breast cancers. A prospective clinicopathologic study. Cancer 1964; 17:1501-1527.
29. Dupont WD, Parl FF, Hartmann WH et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71: 1258-1265.
30. Houlston RS, McCarter E, Parbhoo S, Scurr JH, Slack J. Family history and risk of breast cancer. J Med Genet 1992; 29: 154-157.
31. Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. Monogr Natl Cancer Inst 1994; 16: 23-34.
32. Bilimoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995; 45: 263-278.
33. Bowcock AM. Breast cancer genes. BreastJ 1997; 3(Suppl): 1-6.
34. Kelsey JL, Gammon MD. The epidemiology of breast cancer. CA Cancer J Clin 1991; 41: 146-165.
35. Kelsey JL, Gammon MD. Epidemiology of breast cancer. Epidemiol Rev 1990; 12: 228-240.
36. Kelsey JL, Gammon MD, John ES. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15: 36-47.
37. Brinton LA, Hoover R, Fraumeni Jr JF. Reproductive factors in the aetiology of breast cancer. Br J Cancer 1983; 41: 151-162.
38. Hunter DJ, Willett WC. Diet, body size and breast cancer. Epidemiol Rev 1993; 15: 110-132.
39. World Cancer Research Fund / American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. American Institute for Cancer Research, 1997.
40. Dorgan JF. Physical activity and breast cancer: Is there a link? J Natl Cancer Inst 1998; 90: 1116-1117.
41. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48-65.
42. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059.
43. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
44. John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev 1993; 15:157-162.
45. Miller AB, Howe GR, Sherman GJ et al. Mortality from breast cancer after irradiation during fluoroscopic examination in patients being treated for tuberculosis. N Engl J Med 1989; 321: 1285-1290.
46. Abrahamsen JF, Anderson A, Hannisdal E et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11: 255-260.
47. Sakorafas GH, Tsiotou AG. Genetic predisposition to breast cancer: a surgical perspective. Br J Surg 2000; 87: 149-162.
48. Brisson J, Morrison AS, Khalid N. Mammographic parenchymal features and breast cancer in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988; 80: 1534-1540.
49. Saflas AF, Hoover RN, Brinton LA et al. Mammographic densities and risk of breast cancer. Cancer 1991; 67: 2833-2839.
50. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in general population. JAMA 1998; 279: 922-929.
51. P. Sauven. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer 2004; 40: 653-665.
52. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
53. Ottman R, Pike MC, King MC. Practical guide for estimating risk for familial breast cancer. Lancet 1983; 2: 556-560.
54. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early onset breast cancer. Implications for risk prediction. Cancer 1994; 73: 643-651.
55. Bondy M, Lustbader E, Halabi S et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994; 86: 620-627.
56. Spiegelman D, Golditz GA, Hunter D et al. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994; 86: 600-607.
57. Costantino JP, Gail MH, Pee D et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91: 1541-1548.
58. Smigel K. Breast cancer prevention trial takes off. J Natl Cancer Inst 1992; 84: 669-670.
59. Mackarem G, Roche CA, Hughes KS. The effectiveness of the Gail model in estimating risk for development of breast cancer in women under 40 years of age. Breast J 2001; 7: 34-39.
60. Gail MH, Benichou J. Epidemiology and biostatistics program of the National Cancer Institute. J Natl Cancer Inst 1994; 86: 573-575.
61. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996; 14:103-110.
62. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. The Breast Cancer Linkage Consortium. Risk of cancer in BRCA-1 mutation carriers. Lancet 1994; 343: 692-695.
63. Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol 1996; 14: 1730-1736.
64. Scottish Intercollegiate Guidelines Network (SIGN). Breast cancer in women. A national clinical guideline. SIGN Publication No. 29, 1998.
65. Eccles DM, Evans DGR, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer on behalf of the UK Cancer Family Study Group. J Med Genet 2000; 37: 203-209.
66. Evans DGR, Burnell LD, Hopwood P, Howell A. Perception of risk in women with a family history of breast cancer. Br J Cancer 1993; 67: 612-614.
67. Evans DGR, Blair V, Greenhalgh R, Hopwood P, Howell A. The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer 1994; 70: 934-938.
68. Lerman C, Lustbader E, Rimer B et al. Effects of individualised breast cancer risk counselling: a randomised trial. J Natl Cancer Inst 1995; 87: 286-292.
69. Hopwood P, Long A, Keeling F, Poole C, Evans DGR, Howell A. Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psycho-Oncology 1998; 7: 403-412.
70. Cull A, Anderson EDC, Campbell S, Mackay J, Smyth E, Steel M. The impact of genetic counselling about breast cancer risk on women's risk perceptions and levels of distress. Br J Cancer 1999; 79: 501-508.
71. Watson M, Lloyd S, Davidson J et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer 1999; 79: 868-874.
72. Hopwood P, Shenton A, Fletcher I, Lalloo F, Evans GDR, Howell A. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet 2001; 85: 166-170.
73. Hoskins KF, Stopfer JE, Calzone KA et al. Assessment and counselling for women with a family history of breast cancer: a guide for clinicians. JAMA 1995; 273: 577-585.
74. Austoker J, Mansel RE, Baum M, Sainsbury R, Hobbs R. Guidelines for referral of patients with breast problems. NHS Breast Screening Programme on behalf of the Department of Health Advisory Committee on Breast Cancer Screening 1995.
75. Dixon JM, Mansel RE. Symptoms, assessment and guidelines for referral. Br Med J 1994; 309: 722-726.
76. Austoker J. Cancer prevention in primary care: screening and self examination for breast cancer. Br Med J 1994; 309: 168-174.
77. Burke W, Dly M, Garber J et al. Recommendations for follow up care of individuals with an inherited predisposition to cancer, II. BRCA1 and BRCA2. JAMA 1997; 277: 997-1003.
78. Kanemura S, Tsuji I, Ohuchi N et al. A case control study on the effectiveness of breast cancer screening by clinical examination in Japan. Jpn J Cancer Res 1999; 90: 607-613.
79. Jatoi I. Breast cancer screening. Am J Surg 1999; 177: 518-524.
80. Gui GPH, Hogben RKF, Walsh G, Hern RA, Eeles R. The incidence of breast cancer from screening women according to predicted family history risk; does annual clinical examination add to mammography? Eur J Cancer 2001; 37: 1668-1673.
81. Sirovich BE, Sox HC. Breast cancer screening. Surg Clin North Am 1999; 79: 961-990.
82. Cull A, Anderson ED, Mackay J, Smith E, Steel CM, Prescott R. Risk perception and distress amongst women attending a breast cancer family clinic. Eur J Cancer 1995; 318: 277-285.
83. Bennett IC, Gattas M, Tean B. The genetic basis of breast cancer and its clinical implications. Aust N Z J Surg 1999; 69: 95-105.
84. Rimer BK. Breast cancer screening. In: Harris JR (ed): Diseases of the Breast. Lippincott-Raven: Philadelphia, 1996, pp 307-322.
85. Burhenne HJ, Burhenne LW, Goldberg F et al. Interval breast cancers in the Screening Mammography Program of British Columbia: analysis and classification. Am J Roentgenol 1994; 162: 1067-1071.
86. Tabar L, Duffy S, Burhenne LW. New Swedish breast cancer detection results for women aged 40-49. Cancer 1993; 27: 1437-1448.
87. Elmore JG, Barton MB, Moceri VM et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338: 1089-1096.
88. Kerlikowske K, Carney PA, Geller B et al. Performance of screening mammography among women with and without a first degree relative with breast cancer. Ann Intern Med 2000; 133: 855-863.
89. Macmillan RD. Screening women with a family history of breast cancer-results from the British Familial Breast Cancer Group. Eur J Surg Oncol 2000; 26: 149-152.
90. Moller P, Reis MM, Evans G et al. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group. Dis Markers 1999; 15: 179-186.
91. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000; 36: 514-519.
92. Casey G. The BRCA1 and BRCA2 breast cancer genes. Curr Opin Oncol 1997; 9: 88-93.
93. Lalloo F, Boggis CR, Evans DG, Shenton A, Threlfall AG, Howell A. Screening by mammography, in women with a family history of breast cancer. Eur J Cancer 1998; 34: 937-940.
94. Kollias J, Sibbering DM, Blamey RW et al. Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 1998; 34: 878-883.
95. Kerlikowske K, Grady D, Barclay J et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996; 276: 33-38.
96. Guidance on screening and symptomatic breast imaging. Board of Faculty of Clinical Radiology (2nd edn), Royal College of Radiologists, London 2003.
97. Feig SA. Increased benefit from shorter screening mammography intervals for women aged 40-49 years. Cancer 1997; 80: 2035-2039.
98. Bick U. An integrated early detection concept in women with a genetic predisposition for breast cancer. Radiologe 1997; 37: 591-596.
99. Kolb M, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast ultrasound and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225: 165-175.
100. Brown J, Coulthard A, Dixon AK et al. Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: 78-82.
101. Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-279.
102. Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102.
103. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-3531.
104. Harms SE. Breast magnetic resonance imaging. Semin Ultrasound CT MR 1998; 19: 104-120.
105. Sakorafas GH. The management of women at high risk for development of breast cancer: risk estimation and preventative strategies Cancer Treat Rev 2003; 29: 79-89.
106. Jarrett JR. Prophylactic subcutaneous mastectomy and reconstruction. In: Cohen M, Goldwin RM (eds): Mastery of Plastic and Reconstructive Surgery (vol. II). Boston: Little, Brown and Co, 1994, pp 1276-1282.
107. Soran A, Vogel VG. Optimal management of primary breast cancer. Breast J 1999; 5:81-93.
108. Goodnight JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984; 26: 198-201.
109. Eldar S, Meguid MM, Beattu JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984; 148: 692-695.
110. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-454.
111. Willemsen H, Kaas R, Peterse JH, Rutgers EJ. Breast carcinoma in residual breast tissue after bilateral subcutaneous mastectomy. Eur J Surg Oncol 1998; 24 :331-338.
112. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesth Plast Surg 1989; 13: 15-21.
113. Pennisi VR, Capozzi A, Perez F. Subcutaneous mastectomy data: a preliminary report. Plastic Recon Surg 1997; 59: 53-56.
114. Grann VR, Panageas KS, Whang W et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998; 16: 979-985.
115. Schrag D, Kuntz KM, Garber JE et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336: 1465-1471.
116. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
117. Meijers-Heijboer H, van Geel B, van Putten WJL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
118. Hartmann L, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Jnst 2001; 93: 1633-1637.
119. Lagios MD, Gates EA, Westdahl PR, Richards V, Alpert BS. A guide to the frequency of nipple involvement in breast cancer. Am J Surg 1979; 138: 135-140.
120. Wapnir IL, Rabinovitz B, Greco RS. A reappraisal of prophylactic mastectomy. Surg Gynecol Obstet 1990; 171: 171-184.
121. Meyer L, Ringberg A. A prospective study of psychiatric and psychosocial sequelae of bilateral subcutaneous mastectomy. Scand J Plast Reconstr Surg 1986; 20: 101-107.
122. Lalloo F, Baildam A, Brain A, Hopwood P, Evans DG, Howell A. A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. Eur J Surg Oncol 2000; 26: 711-713.
123. Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-1479.
124. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or 2 mutation. New Engl J Med 2002; 346: 1609-1615.
125. Rebbeck TR, Lynch HI, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or 2 mutations. New Engl J Med 2002; 346: 1616-1622.
126. Fisher B, Constantino JP, Wickerman DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.
127. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998; 352: 98-101.
128. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 1998; 352: 93-97.
129. Veronesi U, Maisonneuve P, Sacchini V et al. Tamoxifen for breast cancer among hysterectomized women. Lancet 2002; 359: 1122-1124.
130. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002; 360: 817-824.
131. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003; 361: 296-300.
132. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999; 281: 2189-2197.
133. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Breast Cancer Res Treat 2001; 65: 125-134.
134. The ATAC Trialists' Group. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
135. Burke W, Daly M, Barber J et al. Recommendations for follow up care of individuals with an inherited predisposition to cancer. JAMA 1997; 277: 145-151.
136. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. N Engl J Med 1992; 327: 319-328.